8月7日，科伦博泰生物盘中上涨3.15%，报524.0港元，成交额7461.73万港元。
消息面上，公司近日公告新型双载荷ADC药物SKB565获国家药监局临床试验批准，用于治疗晚期实体瘤，系公司首个进入临床阶段的双载荷抗体偶联药物，标志着其"ADC+IO"一体化策略迈出关键一步。同时，公司将于8月17日召开董事会审议中期业绩，市场对业绩兑现预期升温。此前高盛、摩根大通分别上调目标价至582.95港元及648港元，维持买入评级，多重催化共振推动资金关注度提升。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.